How Ozempic (semaglutide) works — GLP-1 receptor agonism, insulin secretion, glucagon suppression, gastric emptying delay, appetite effects, and what this means for diabetes and weight.
Short answer: Ozempic is a GLP-1 receptor agonist: it mimics the gut hormone GLP-1 to increase glucose-dependent insulin release, suppress glucagon, slow gastric emptying, and reduce appetite through brain satiety pathways. Result: lower blood sugar plus reduced food intake — the two effects behind its diabetes and weight effects.
GLP-1 (glucagon-like peptide-1) is an incretin hormone your gut releases after eating. It tells the pancreas to release insulin (only when glucose is high), tells the liver to make less glucose via glucagon suppression, slows how fast the stomach empties, and signals fullness to appetite centers in the brain.
Semaglutide is a modified version of human GLP-1 engineered to last a week — albumin binding protects it from breakdown, so one weekly injection provides continuous effect.
Semaglutide's ~7-day half-life means steady drug levels with weekly dosing. Steady state arrives after 4–5 weeks; early weeks use the lower starting dose to let the GI system adapt.
Ozempic program | Nepal treatment guide | FAQs | What is Ozempic? | Dosage | Who should avoid | Drug interactions | Monitoring | Results | Vs Wegovy vs Mounjaro | Diet & exercise | Price in Nepal | Stree Clinic | Lead Doctor | Weight loss | Diabetes care | Side effects | Success stories | Editorial policy | How to get Ozempic | Results timeline | Meal plan | Injection guide | Storage & cold chain | Myths vs facts | नेपालीमा | Conditions treated | Clinical trials | BMI eligibility | BMI calculator | Without diabetes | Fake semaglutide warning | Ozempic & alcohol | Vs Saxenda | PCOS | Fatty liver | Kidney disease | Prediabetes | Heart health | Alternatives | Ozempic face | Hair loss | Stopping Ozempic | For men | For women | Not losing weight | Semaglutide in Nepal | GLP-1 treatment | Find a doctor | Availability | Medical weight loss | Obesity treatment | Diabetes doctor | Eligibility | Insulin resistance | Wegovy in Nepal | Mounjaro in Nepal | Rybelsus in Nepal | Areas served | Find a specialist | Weight loss medication | Book consultation | Ozempic vs keto | Vs low-carb | Vs calorie deficit | Vs exercise | Vs diet & exercise | Vs intermittent fasting | Vs fasting | Vs natural weight loss | Vs lifestyle changes | Vs medical weight mgmt | Vs dietitian-guided | Vs bariatric surgery | Request assessment
No — it stimulates your own insulin release when glucose is high. It's a GLP-1 receptor agonist, a different class entirely.
Partially — it reduces appetite on its own, but clinical outcomes (weight, HbA1c) are best combined with dietary change and activity. It's a tool that makes adherence easier, not a substitute.
GLP-1 receptor activity starts with the first dose; appetite effects are usually felt within days, glucose effects within weeks, weight effects over months.
Sources: FDA Ozempic prescribing information (DailyMed), Novo Nordisk, ADA Standards of Care, SUSTAIN/STEP trial publications (NEJM/Lancet), WHO.
Browse all pages